Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01872078

NCT01872078
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You are a woman between 18 and 45 years old (inclusive)
  • You have suitable veins that can be used for blood draws or an IV line
  • Your body mass index (BMI) is between 18 and 40 (a measure based on your height and weight)
  • You have been diagnosed with polycystic ovary syndrome (PCOS)
  • You have absent periods or very infrequent periods (6 or fewer per year)
  • Your pregnancy blood test at the initial screening appointment came back negative
  • Your pregnancy urine test before being assigned to a treatment group came back negative
  • You are not currently breastfeeding
  • You have not been pregnant in the 6 months before your screening appointment

Who may not be able to join:

  • You are approaching menopause or have already reached natural menopause, based on a specific hormone level in your blood (confirm with trial site)
  • You had a period within the month before your first study visit
  • You have had your uterus removed, both ovaries removed, or both
  • You have or have had a significant health condition or abnormality, especially anything that causes unusual vaginal bleeding
  • If you recently stopped taking the contraceptive pill, you may not be eligible if a certain hormone level in your blood is found to be too low when retested around the time of your first study visit (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
AstraZeneca
Registry
clinicaltrials_gov
Start date
1 June 2013
Est. completion
1 July 2014

Where this trial is recruiting

🇩🇪 Germany 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Lutenising Hormone (LH) AUC(0-8) Ratio to Baseline at Day 7

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov